NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Thanks Chiugray. This is my reasoned interpretation based on Advent’s MHRA licence, SEC filings, and the Eden patent.

Early filings listed 2 Grade B artisan suites and a planned Grade C lab but didn’t mention the 3 active Grade C cleanrooms already licensed under MHRA MIA 54923 or the 2 Grade D rooms that support them. After reviewing Advent’s GMP data and Linda Powers’ 2024 ASM remarks, it became clear my earlier footprint was incomplete.

This was also made clear in Bruce’s post:

🔗

Exactly. Correlates with this yearly magazine. So much nonsens spouted about this. They have C cleanrooms.

👍🏻 pic.twitter.com/xfpT0au7Fx

— 🇩🇰 The Danish Dude 🇬🇱 (@FlemmingBruce) October 6, 2025

Advent now has 3 Grade C rooms (Eden ready) plus 2 more Grade C suites at the leased external GMP facility, supported by 2 Grade D prep rooms. That’s 5 Grade C suites available now, backed by Grade D staging that keeps them cycling continuously.

At the 2024 ASM, Linda Powers said each Grade C lab can make ~1–1.1 K patient doses/yr and full build-out could reach ~15 K patients annually. All new Grade C space was designed for Eden validation, so her figure likely included Eden in principle but not its fully optimized throughput.

Eden wasn’t GMP-validated yet (Mar 31 2025 10-Q lists validation pending). Before validation, a CEO must quote conservative, regulator-safe numbers.

Eden’s patent describes a closed, automated DC-vaccine system using single-use modular cartridges. Each cartridge is a sterile micro-environment that swaps immediately after its 8-day maturation, eliminating downtime and turning each unit into a continuously cycling bioreactor.

Cartridge logic:

Each Grade C suite, once Eden runs continuously, could produce ~2.7–3× its ASM baseline (1–1.1 K to 2.7–3.3 K per suite/yr).

Math:

• 5 Grade C suites × 2.7–3.3 K = ˜ 13.5–16.5 K patients/yr

• + 2 Grade B suites (˜ 1–1.2 K total) = ˜ 14.5–17.7 K combined once Eden validated

The 3–3.3 K per-suite figure isn’t arbitrary; it follows Eden’s patent logic. The cartridge system removes idle time, Grade C allows more units per room, and Grade D staging keeps production constant. The difference between the conservative (~5.5 K) and optimized (~15 K) views is simply whether Linda Powers’ 15 K patients/year represents the long-term goal or an achievable near-term reality once Eden is fully validated.

3 Advent Grade C rooms form the base for validation; 2 new Grade C pods are under build; the leased facility prevents construction delays so scaling can start now.

Even conservatively, 5 suites × 1.1 K ˜ 5.5 K patients/yr. With Eden automation, the model aligns with the ~15 K capacity Linda Powers outlined.

All math and assumptions are my own, based on public data and filings.